MK-571 sodium (Synonyms: L-660711 sodium)

Name: MK-571 sodium
Brand: MedChemExpress
SKU: HY-19989A
Rating: 5.0 (33 reviews)

Cat. No.: HY-19989A Purity: 99.75%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.

For research use only. We do not sell to patients.

CAS No. : 115103-85-0

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 33 publication(s) in Google Scholar

Other Forms of MK-571 sodium:

MK-571 In-stock

33 Publications Citing Use of MCE MK-571 sodium

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

Cell Imaging/Staining

In Vivo Efficacy Study

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Jun 3:154210. [Abstract]; MK-571 (5 μM, 1 h) dilates the bile canalicular area in HepaRG cells.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Jun 3:154210. [Abstract]; MK-571 (5 μM, 6 h) reduced the expression of NTCP, BSEP, and MRP3 in HepaRG cells.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]; Cells were treated with the ABCC1 inhibitor MK-571 sodium (10 μM) and MRTX849 for 3 days, followed by CCK-8 assays. The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]; Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 sodium for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8. [Abstract]; HT1080 and HUH7 cells were pretreated with Verapamil (20 μM) or MK-571 sodium (40 μM) for 2 h and then treated with DMSO or RU486 (5 μM) together with concentration gradient of RSL3 (0–10 μM) for 24 h. Cell viability was measured by CCK-8 (n = 3).

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]; MK-571 (5 μM, 30 min) increased the fluorescence intensity of DOX-inducible CD10⁺ PTEC CMFDA metabolites.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]; Survival curves for mice subjected to SD (SR means 48 h of recovery after SD) with oral administration of MK-571 sodium (0.1 mg/mL) (n = 10) in the drinking water compared with water controls (n = 10). The results showed that MK-571 sodium protected against SD-induced mortality.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep;129:110506. [Abstract]; MK-571 (50 μM, 10 min) increased the accumulation of [3H]-MVC in BeWo cells.

: MK-571 sodium purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]; The MRP1 inhibitor MK-571 sodium (50 µM; 1 h) decreased A–B MeHg transport in MDCKII-MRP1 cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Leukotriene Receptor Isoform Specific Products:

View All Isoforms

LTB₄ LTC₄/CysLT₂ LTD₄/CysLT₁ LTE₄

View All LPL Receptor Isoform Specific Products:

View All Isoforms

LPAR1 LPAR2 LPAR3 LPAR5 S1PR1 S1PR2 S1PR3 S1PR4 S1PR5

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

LTD₄

0.22±0.15 nM (Ki, In guinea pig lung)

LTD₄

2.1±1.8 nM (Ki, In human lung)

LTD₄

10.5 (pA2)

LTE₄

10.4 (pA2)

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	7.57 μM Compound: MK-571	Inhibition of human MRP1 in human 2008 cells Inhibition of human MRP1 in human 2008 cells	[PMID: 18707884]
MDCK-II	IC₅₀	20.7 μM Compound: MK-571	Inhibition of human MRP2 expressed in dog MDCK2 cells Inhibition of human MRP2 expressed in dog MDCK2 cells	[PMID: 18707884]
MDCK-II	IC₅₀	> 30 μM Compound: MK571	Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux Inhibition of human MRP1 transfected in MDCK2 cells assessed as inhibition of calcein-AM efflux	[PMID: 26774038]

In Vitro

MK571 sodium (15 μM, 1 h) markedly suppresses constitutive and Ag-stimulated S1P secretion from RBL-2H3 cells and mast cells, and inhibits Fluo-3 efflux^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	RBL-2H3 cells, human LAD2 mast cells
Concentration:	15 μM
Incubation Time:	1 h
Result:	Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.

In Vivo

MK-571 sodium (0-0.5 mg/kg, orally, once) produces dose-dependent inhibition of the duration of antigen-induced dyspnea in conscious sensitized rats treated with Methysergide (3 μg/kg)^[1].
MK-571 sodium (0-1 mg/kg, orally, once) blocks LTD₄- and Ascaris-induced bronchoconstriction in conscious squirrel monkeys^[1].
MK-571 sodium (0-25 mg/kg, orally, daily, for 2 more weeks) shows reversal of hypoxic pulmonary hypertension (PH), and protects mice from hypoxic PH^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3 μg/kg methysergide, 5 min before antigen chdlenge)^[1]
Dosage:	0.5, 0.15, and 0.05 mg/kg
Administration:	Orally, once, 1 or 4 h before challenge
Result:	Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED₅₀ values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED₅₀ of 0.068 (95% CI, 0.83-0.14) mg/kg.

Animal Model:	Csnscisus squirrel msnkeys^[1]
Dosage:	0.1, 0.5, and 1 mg/kg
Administration:	Orally, once, 2 h prior to challenge with Ascaris antigen
Result:	Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in R_L and decreases in C_dyn at 1 mg/kg.

Animal Model:	FVB (Friend virus B-type) mice (Mrp4^–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O₂) in a ventilated chamber for 28 days)^[2]
Dosage:	0, 5, and 25 mg/kg
Administration:	Orally, daily, for 2 more weeks, maintain in hypoxic conditions
Result:	Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.

Molecular Weight

537.07

Formula

C₂₆H₂₆ClN₂NaO₃S₂

CAS No.

115103-85-0

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(O[Na])CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (93.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8620 mL	9.3098 mL	18.6195 mL
5 mM	0.3724 mL	1.8620 mL	3.7239 mL
10 mM	0.1862 mL	0.9310 mL	1.8620 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (4.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.17 mg/mL (4.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.75%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (248 KB) HNMR (364 KB) RP-HPLC (241 KB) MS (79 KB)

Handling Instructions (2659 KB)

References

[1]. Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D₄ receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28. [Content Brief]

[2]. Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97. [Content Brief]

[3]. Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8620 mL	9.3098 mL	18.6195 mL	46.5489 mL
	5 mM	0.3724 mL	1.8620 mL	3.7239 mL	9.3098 mL
	10 mM	0.1862 mL	0.9310 mL	1.8620 mL	4.6549 mL
	15 mM	0.1241 mL	0.6207 mL	1.2413 mL	3.1033 mL
	20 mM	0.0931 mL	0.4655 mL	0.9310 mL	2.3274 mL
	25 mM	0.0745 mL	0.3724 mL	0.7448 mL	1.8620 mL
	30 mM	0.0621 mL	0.3103 mL	0.6207 mL	1.5516 mL
	40 mM	0.0465 mL	0.2327 mL	0.4655 mL	1.1637 mL
	50 mM	0.0372 mL	0.1862 mL	0.3724 mL	0.9310 mL
	60 mM	0.0310 mL	0.1552 mL	0.3103 mL	0.7758 mL
	80 mM	0.0233 mL	0.1164 mL	0.2327 mL	0.5819 mL

MK-571 sodium Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MK-571 sodium (Synonyms: L-660711 sodium)

Customer Review

Other Forms of MK-571 sodium:

MK-571 sodium Related Antibodies

33 Publications Citing Use of MCE MK-571 sodium

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Leukotriene Receptor Isoform Specific Products:

View All LPL Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

MK-571 sodium Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MK-571 sodium Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report